<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879383</url>
  </required_header>
  <id_info>
    <org_study_id>C-30000</org_study_id>
    <nct_id>NCT02879383</nct_id>
  </id_info>
  <brief_title>Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)</brief_title>
  <official_title>Evaluation of the Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fractyl Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fractyl Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Revita System is intended to improve glycemic control in patients with Type 2 diabetes
      who have preserved pancreatic beta cell function and whose diabetes is poorly controlled with
      oral anti-diabetic medications. The purpose of this study is to demonstrate the efficacy and
      safety of the Fractyl DMR Procedure using the Revita System compared to a sham procedure for
      the treatment of uncontrolled type 2 diabetes.

      Subjects randomized to the DMR procedure are followed per protocol for 48 Weeks. The Sham
      treatment arm will cross over to receive the DMR treatment at 24 weeks with background
      medications held constant from 24-48 weeks of follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, randomized, prospective, double-blinded (subject and
      endocrinologist) trial of type 2 diabetes patients sub-optimally controlled on 2 oral
      anti-diabetic medications comparing the Fractyl DMR procedure to sham procedure. Subjects who
      meet all criteria after screening are randomized 1:1 (DMR to sham), with double blinding
      (subject and endocrinologist). The endoscopist is not blinded.

      All subjects will participate in a 4 week oral anti-diabetic medication run-in period before
      the index procedure to confirm lack of blood glucose control in conjunction with medication
      compliance and nutritional counseling and to also allow withdrawal from hypoglycemic
      anti-diabetic medications (i.e. sulfonylurea and meglitinide classes). Subjects randomized to
      the DMR procedure are followed per protocol for 48 Weeks.

      Subjects randomized to the sham procedure are followed for 24 weeks and then offered to cross
      over to the DMR procedure. Cross-over subjects are then followed per protocol for an
      additional 48 Weeks. The Sham treatment arm will cross over to receive the DMR treatment at
      24 weeks with background medications held constant from 24-48 weeks of follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at 24 weeks in hemoglobin A1c (HbA1c), DMR vs Sham.</measure>
    <time_frame>24 Weeks post-procedure</time_frame>
    <description>The primary efficacy endpoint is the change from baseline at 24 weeks in HbA1c, DMR vs Sham</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following at 12 weeks in DMR vs. Sham</measure>
    <time_frame>12 Weeks post-procedure</time_frame>
    <description>Magnetic Resonance Fat Fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) from baseline in the following at 24 weeks in DMR vs. Sham</measure>
    <time_frame>24 Weeks post-procedure</time_frame>
    <description>Fasting Plasma Glucose (FPG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight from baseline in the following at 24 weeks in DMR vs. Sham</measure>
    <time_frame>24 Weeks post-procedure</time_frame>
    <description>Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 24 weeks in DMR vs. Sham</measure>
    <time_frame>24 Weeks post-procedure</time_frame>
    <description>Fibrosis-4 Index for Liver Fibrosis (FIB-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Albumin/Creatinine Ratio (UACR) from baseline in the following at 24 weeks in DMR vs. Sham</measure>
    <time_frame>24 Weeks post-procedure</time_frame>
    <description>Urine Albumin/Creatinine Ratio (UACR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG from baseline in the following at 48 weeks in DMR subjects</measure>
    <time_frame>48 Weeks post-procedure</time_frame>
    <description>FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline in the following at 48 weeks in DMR subjects</measure>
    <time_frame>48 Weeks post-procedure</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Noninsulin-Dependent Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DMR Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the DMR procedure are followed per protocol for 48 Weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Unblinding to occur at 24 Weeks: Sham treatment arm to cross over to receive DMR treatment at 24 Weeks with background medications held constant from 24 - 48 Weeks of follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DMR Procedure</intervention_name>
    <description>The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.</description>
    <arm_group_label>DMR Procedure</arm_group_label>
    <other_name>DMR</other_name>
    <other_name>Revita</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>The sham procedure will consist of placing the Revita Catheter as described above into the duodenum and leaving it in place for a minimum of 45 minutes and then removing it from the patient.</description>
    <arm_group_label>Sham Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 28-75 years of age

          2. Diagnosed with Type 2 Diabetes and evidence of preserved insulin secretion. Fasting
             insulin &gt; 7 μU/ mL.

          3. HbA1c of 7.5 - 10.0% (59-86 mmol/mol)

          4. Body Mass Index (BMI) ≥ 24 and ≤ 40 kg/m2

          5. Currently taking one or more oral glucose lowering medications of which one must be
             Metformin, with no changes in dose or medication in the previous 12 Weeks prior to
             study entry

          6. Able to comply with study requirements and understand and sign the informed consent

        Exclusion Criteria:

          1. Diagnosed with Type 1 Diabetes or with a history of ketoacidosis

          2. Current use of Insulin

          3. Current use of Glucagon-like peptide-1 (GLP-1) analogues

          4. Hypoglycemia unawareness or a history of severe hypoglycemia (more than 1 severe
             hypoglycemic event, as defined by need for third-party-assistance, in the last year)

          5. Known autoimmune disease, as evidenced by a positive Anti- Glutamic Acid Decarboxylase
             (GAD) test, including Celiac disease, or pre-existing symptoms of systemic lupus
             erythematosus, scleroderma or other autoimmune connective tissue disorder

          6. Active H. pylori infection (Participants with active H. pylori may continue with the
             screening process if they are treated via medication and re-testing verifies the
             condition has resolved.)

          7. Previous GI surgery that could affect the ability to treat the duodenum such as
             subjects who have had a Bilroth 2, Roux-en-Y gastric bypass, or other similar
             procedures or conditions

          8. History of chronic or acute pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jay Caplan</last_name>
    <phone>781-902-8811</phone>
    <email>jay@fractyl.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aruna Vedala</last_name>
    <phone>781-325-8853</phone>
    <email>aruna@fractyl.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aicha Hamouda</last_name>
      <phone>+32 2 555 72 91</phone>
      <email>Aicha.Hamouda@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Mona Hammam</last_name>
      <phone>+32 (0) 2 555 47 64</phone>
      <email>mona.hammam@erasme.ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques Deviere, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Crenier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Achten</last_name>
      <email>sophie.achten@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Raf Bisschops, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Mertens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de medicina da Universidade de São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Carolina Candido</last_name>
      <phone>+55 11 94131-4975</phone>
      <email>ana.candido@hc.fm.usp.br</email>
    </contact>
    <investigator>
      <last_name>Eduardo G Hourneaux de Moura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ABC Hospital</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Rosa</last_name>
      <email>bruno.rosa@fmabc.br</email>
    </contact>
    <investigator>
      <last_name>Eduardo Grecco</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Teresa Santomauro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli (Sacro Cuore)</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Gualtieri</last_name>
      <email>carolina.gualtieri@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Geltrude Mingrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guido Costamagna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital &amp; Humanitas University Via Manzoni 56, Rozzano</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Finati</last_name>
      <email>elena.finati@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Lania</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Peddie</last_name>
      <email>hilary.peddie@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>John Morris, MB FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Drummond, BSc, MBCHB, MD, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cormac McGee, MD</last_name>
      <phone>07572 130 166</phone>
      <email>RevitaTrial@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rehan Haidry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Batterham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College, Denmark Hill</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Henderson-Wilson</last_name>
      <email>Marcia.Henderson-Wilson@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>David Hopkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre campus, Nottingham University Hospitals NHS Trust, Derby Road</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayna Babington</last_name>
      <email>Gayna.Babington@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Krish Ragunath, MD FRCP FASGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Idris Iskander</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>International Diabetes Federation (2014). The Global Burden. In IDF, International Diabetes Atlas (6th ed., pp 30).</citation>
  </reference>
  <reference>
    <citation>The diabetes pandemic. Lancet. 2011 Jul 9;378(9786):99. doi: 10.1016/S0140-6736(11)61068-4.</citation>
    <PMID>21742159</PMID>
  </reference>
  <reference>
    <citation>Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012 Apr 5;366(14):1319-27. doi: 10.1056/NEJMcp1013127. Review.</citation>
    <PMID>22475595</PMID>
  </reference>
  <reference>
    <citation>Cummings DE. Metabolic surgery for type 2 diabetes. Nat Med. 2012 May 4;18(5):656-8. doi: 10.1038/nm.2773.</citation>
    <PMID>22561818</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Bloom SR, Rubino F. At the heart of the benefits of bariatric surgery. Nat Med. 2012 Mar 6;18(3):358-9. doi: 10.1038/nm0312-358.</citation>
    <PMID>22395701</PMID>
  </reference>
  <reference>
    <citation>Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006 Nov;244(5):741-9.</citation>
    <PMID>17060767</PMID>
  </reference>
  <reference>
    <citation>Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012 Jul;22(7):1084-96. doi: 10.1007/s11695-012-0621-4.</citation>
    <PMID>22359255</PMID>
  </reference>
  <reference>
    <citation>Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011 Jul;21(7):896-901. doi: 10.1007/s11695-011-0412-3.</citation>
    <PMID>21559794</PMID>
  </reference>
  <reference>
    <citation>Nguyen KT, Billington CJ, Vella A, Wang Q, Ahmed L, Bantle JP, Bessler M, Connett JE, Inabnet WB, Thomas A, Ikramuddin S, Korner J. Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass. Diabetes. 2015 Sep;64(9):3104-10. doi: 10.2337/db14-1870. Epub 2015 Apr 21.</citation>
    <PMID>25901097</PMID>
  </reference>
  <reference>
    <citation>Blanco J, Jiménez A, Casamitjana R, Flores L, Lacy A, Conget I, Vidal J. Relevance of beta-cell function for improved glycemic control after gastric bypass surgery. Surg Obes Relat Dis. 2014 Jan-Feb;10(1):9-13; quiz 189-90. doi: 10.1016/j.soard.2013.07.020. Epub 2013 Aug 30.</citation>
    <PMID>24342036</PMID>
  </reference>
  <reference>
    <citation>Nannipieri M, Mari A, Anselmino M, Baldi S, Barsotti E, Guarino D, Camastra S, Bellini R, Berta RD, Ferrannini E. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011 Sep;96(9):E1372-9. doi: 10.1210/jc.2011-0446. Epub 2011 Jul 21.</citation>
    <PMID>21778221</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE; 2004 ABS Consensus Conference. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis. 2005 May-Jun;1(3):358-68. Review.</citation>
    <PMID>16925248</PMID>
  </reference>
  <reference>
    <citation>Gniuli D, Calcagno A, Dalla Libera L, Calvani R, Leccesi L, Caristo ME, Vettor R, Castagneto M, Ghirlanda G, Mingrone G. High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia. 2010 Oct;53(10):2233-40. doi: 10.1007/s00125-010-1830-9. Epub 2010 Jun 30.</citation>
    <PMID>20585935</PMID>
  </reference>
  <reference>
    <citation>Verdam FJ, Greve JW, Roosta S, van Eijk H, Bouvy N, Buurman WA, Rensen SS. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab. 2011 Feb;96(2):E379-83. doi: 10.1210/jc.2010-1333. Epub 2010 Nov 17.</citation>
    <PMID>21084402</PMID>
  </reference>
  <reference>
    <citation>Verdam FJ, Schouten R, Greve JW, Koek GH, Bouvy ND. An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery. J Obes. 2012;2012:597871. doi: 10.1155/2012/597871. Epub 2012 Aug 21.</citation>
    <PMID>22957215</PMID>
  </reference>
  <reference>
    <citation>Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, Muñoz R, Bambs C, Guzmán S, Ibáñez L, Gersin K. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012 Jun;255(6):1080-5. doi: 10.1097/SLA.0b013e31825498c4.</citation>
    <PMID>22534421</PMID>
  </reference>
  <reference>
    <citation>Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, Prieto C, Ramos A, Galvao M, Gersin KS, Sorli C. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009 Nov;11(11):725-32. doi: 10.1089/dia.2009.0063.</citation>
    <PMID>19905889</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

